Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 5, 2004, Pages 1199-1207

  Xu, Ze Qi ^a   Barrow, William W ^b   Suling, William J ^c   Westbrook, Louise ^c   Barrow, Esther ^b   Lin, Yuh Meei ^a   Flavin, Michael T ^a  

^a Advanced Life Sciences Inc   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 OXOCALANOLIDE A; 7,8 DIHYDRO 12 OXOCALANOLIDE A; 7,8 DIHYDROCALANOLIDE B; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CALANOLIDE A; CALANOLIDE B; CALANOLIDE D; CERULENIN; ETHAMBUTOL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ISONIAZID; POLYMYXIN B; PYRANOCOUMARIN DERIVATIVE; RIFAMPICIN; SOULATTROLIDE; STREPTOMYCIN; UNCLASSIFIED DRUG;

ACUTE MONOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BACTERIAL REPRODUCTION; CELL LINE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOPHORE; PROTEIN SYNTHESIS; RNA SYNTHESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 1342300734     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2003.11.012     Document Type: Article

References (32)

1. Raviglione M.C., Snider D.E., Koch A. J. Am. Med. Assoc. 273:1995;220.
2. Butler D. Nature. 406:2000;670.
3. Harries, A. D.; Mahler, D. TB/HIV, a Clinical Manual Published by the World Health Organization. Stabilimento Tipografico Ferrero s.r.l.-Romano Canavese (TO): Italy, 1996.
4. Floyd K., Blanc L., Raviglione M., Lee J.-W. Science. 295:2002;2040.
5. Gupta R., Kim J.Y., Espinal M.A., Caudron J.-M., Pecoul B., Farmaer P.E., Raviglione M.C. Science. 293:2001;1049.
6. Heifets L., Sanchez T., Vanderkolk J., Pham V. Antimicrob. Agents Chemother. 43:1999;25.
7. Cynamon M.H., Klemens S.P., Sharpe C.A., Chase S. Antimicrob. Agents Chemother. 43:1999;1189.
8. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., Kreiswirth B.N., Barry C.E., Baker W.R. Nature. 405:2000;962.
9. Gerard J., Lloyd R., Barsby T., Haden P., Kelly M.T., Anderson R.J. J. Nat. Prod. 60:1997;223.
10. El Sayed K.A., Bartyzel P., Shen X., Perry T.L., Zjawiony J.K., Hamann M.T. Tetrahedron. 56:2000;949.
11. Lin Y.-M., Zhou Y., Flavin M.T., Zhou L.-M., Nie W., Chen F.-C. Bioorg. Med. Chem. 10:2002;2795.
12. Lin Y.-M., Flavin M.T., Cassidy C.S., Mar A., Chen F.-C. Bioorg. Med. Chem. Lett. 11:2001;2101.
13. Xu Z.-Q., Jenta T.R., Flavin M.T. Curr. Opin. Drug Discov. Develop. 3:2000;155.
14. Ziegler-Heitbrock H.W., Blumenstein M., Thiel E., Fütterer A., Herzog V., Wirtz A. Int. J. Cancer. 41:1988;456.
15. Barrow E.L.W., Winchester G.A., Stass J.K., Quenelle D.C., Barrow W.W. Antimicrob. Agents Chemother. 42:1998;2682.
16. Barrow W.W. Rev. Sci. Tech. Off. Int. Epiz. 20:2001;55.
17. Borin M.T., Chambers J.H., Carel B.J., Gagnon S., Freimuth W.W. Clinical Pharmacol. Ther. 61:1997;544.
18. Dye C., Williams B.G., Espinal M.A., Raviglione M.C. Science. 295:2002;2042.
19. Levin M.E., Hatfull G.F. Mol. Microbiol. 8:1993;277.
20. Kashman Y., Gustafson K.R., Fuller R.W., Cardellina J.H., McMahon J.B., Currens M.J., Buckheit R.W. Jr., Hughes S.H., Cragg G.M., Boyd M.R. J. Med. Chem. 35:1992;2735.
21. Ruckle, J.; Giltner, J.; Creagh, T.; Dutta, B.; Tolbert, D.; Xu, Z.-Q. IN: Program and Abstracts, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Jan.-Feb., 1999, Abstract 606.
22. Creagh T., Ruckle J.L., Tolbert D., Giltner J., Eiznhamer D.A., Dutta B., Flavin M.T., Xu Z.-Q. Antimicrob. Agents Chemother. 45:2001;1379.
23. Eiznhamer D.A., Creagh T., Ruckle J.L., Tolbert D.T., Giltner J., Dutta B., Flavin M.T., Jenta T., Xu Z.-Q. HIV Clin. Trials. 3:2002;435.
24. Lin Y.-M., Anderson H.M., Jenta T.R., Williams M.J., Flavin M.T., Xu Z.-Q. Pharm. Biol. 37:1999;71.
25. Flavin M.T., Rizzo J.D., Khilevich A., Kucherenko A., Sheinkman A.K., Vilaychack V., Lin L., Chen W., Greenwood E.M., Pengsuparp T., Pezzuto J.M., Hughes S.H., Flavin T.M., Cibulski M., Boulanger W.A., Shone R.L., Xu Z.-Q. J. Med. Chem. 39:1996;1303.
26. Galinis D.L., Fuller R.W., McKee T.C., Cardellina J.H., Gulakowski R.J., McMahon J.B., Boyd M.R. J. Med. Chem. 39:1996;4507.
27. Khilevich A., Mar A., Flavin M.T., Rizzo J.D., Dzekhtser S., Brankovic D., Lin L., Zhang H., Chen W., Liao S., Zembower D.E., Xu Z.-Q. Tetrahedron: Asymmetry. 7:1996;3315.
28. Collins L.A., Franzlau C.G. Antimicrob. Agents Chemother. 41:1997;1004.
29. Tuberculosis drug screening program. Antimicrob. Agents Chemother. 2001, 45, 1943.
30. Suling W.J., Seitz L.E., Pathak V., Westbrook L., Barrow E.W., Zywno-van-Ginkel S., Reynolds R.C., Piper J.R., Barrow W.W. Antimicrob. Agents Chemother. 44:2000;2784.
31. Wright E.L., Quenelle D.C., Suling W.J., Barrow W.W. Antimicrob. Agents Chemother. 40:1996;2206.
32. Wayne L.G. Infect. Immun. 17:1977;528.